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Abstract 20 
Organoids are in vitro cultures of miniature fetal or adult organ-like structures. Their potentials 21 
for use in tissue and organ replacement, disease modeling, toxicology studies, and drug 22 
discovery are tremendous. Currently, major challenges facing human organoid technology 23 
include (i) improving the range of cellular heterogeneity for a particular organoid system, (ii) 24 
mimicking the native micro- and matrix-environment encountered by cells within organoids, and 25 
(iii) developing robust protocols for the in vitro maturation of organoids that remain mostly fetal-26 
like in cultures. To tackle these challenges, we advocate the principle of reverse engineering that 27 
replicates the inner workings of in vivo systems with the goal of achieving functionality and 28 
maturation of the resulting organoid structures with the input of minimal intrinsic (cellular) and 29 
environmental (matrix and niche) constituents. Here, we present an overview of organoid 30 
technology development in several systems that employ cell materials derived from fetal and 31 
adult tissues and pluripotent stem cell cultures. We focus on key studies that exploit the self-32 
organizing property of embryonic progenitors and the role of designer matrices and cell-free 33 
scaffolds in assisting organoid formation. We further explore the relationship between adult stem 34 
cells, niche factors, and other current developments that aim to enhance robust organoid 35 
maturation. From these works, we propose a standardized pipeline for the development of future 36 
protocols that would help generate more physiologically relevant human organoids for various 37 
biomedical applications. 38 
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1. INTRODUCTION 43 
Strong predictability of preclinical testing is vital to success in clinical trials. Current 44 
preclinical tests for efficacy, toxicity, and pharmacokinetics are far from perfect. While animal 45 
models have been regarded as the gold standard, the use of laboratory animals continues to pose 46 
ethical questions. The considerable animal species differences in reactions to drugs (Burkina et 47 
al., 2017) and in disease phenotypes (Seok et al., 2013) also significantly lower the accuracy of 48 
preclinical predictions. For some diseases—such as infectious diseases—no relevant animal 49 
models are available. It has been reported that only 8% of the predictions of cancer drugs 50 
generated from animal models have been successfully translated into human clinical trials (Mak 51 
et al., 2014). In addition to animal models, in vitro two-dimensional (2D) cell cultures are also 52 
widely used for preclinical testing. The predictions from 2D cell cultures, however, are often 53 
difficult to interpret and could be misleading because cells cultured in 2D environments often 54 
lose their functionality and have altered phenotypes that are different from those in in vivo 55 
tissues and organs. In recent years, the United States Environmental Protection Agency (EPA), 56 
the National Institute of Health (NIH), and the Defense Advanced Research Projects Agency 57 
(DARPA) have initiated programs such as the ToxCast Programme and the Microphysiological 58 
Systems (MPS) Program to advocate the development of human cellular models to assess the 59 
safety and/or the efficacy of environmental chemicals (Kleinstreuer et al., 2014) and drugs 60 
(Fabre et al., 2014). In particular, the DARPA MPS program promotes the development of 61 
organs-on-chips and human-on-chips approaches to synthesize in vitro three-dimensional (3D) 62 
human tissues derived from cultured cells on bioengineered platforms to bring together native-63 
like tissue architecture and physiology for highly-predictive and physiologically-relevant 64 
monitoring of the functions and effects of toxic substances and drugs at the organ- or body-levels. 65 
There is an urgent need to develop more physiologically relevant, efficient, and robust protocols 66 
to advance technology that synthesizes human tissues. 67 
 1.1 DEFINING ORGANOIDS. The term organoid was first employed in an oncology 68 
study to indicate a pathological and tumor-like tissue mass formed in a human infant 69 
(Kretzschmar and Clevers, 2016; Smith and Cochrane, 1946). The term has since been used in 70 
the medical field to describe a multisystem disorder, called organoid nevus syndrome, related to 71 
benign outgrowths of sebaceous glands on the skin and the eye of affected individuals (Shields et 72 
al., 1996). Organoid was loosely used in experiments to denote transplanted tissues or the 73 
resultant tissue masses from transplants (Waddell, 1949; Yoshida et al., 1980). Increasingly 74 
frequent in the late 1980s and early 1990s, organoid was employed in developmental biology 75 
experiments to denote high-density or organ-like cultures generated through aggregation and cell 76 
sorting of dissociated animal cells and tissues (Elkasaby et al., 1991; Ridgeway et al., 1986; 77 
Schroter-Kermani et al., 1991). The two decades following this were characterized by the advent 78 
of embryonic (ESC) and induced pluripotent (iPSC) stem cell cultures derived from rodent, 79 
primate, and human embryos (Martin, 1980; Thomson et al., 1998; Thomson et al., 1995) and 80 
somatic cells (Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007; Yu et 81 
al., 2007), as well as the discovery of adult stem cells in various tissues including retina (Tropepe 82 
et al., 2000), bone marrow (Wilson and Trumpp, 2006), epidermis (Clayton et al., 2007), 83 
intestinal crypts (Clevers, 2013), stomach glands (Leushacke et al., 2013), testis (Klein et al., 84 
2010), esophagus (Doupe et al., 2012), and brain (Fuentealba et al., 2012). Following these 85 
successive breakthroughs, the definition of organoid evolved to describe the in vitro 3D 86 
structures derived from differentiating cultures of ESCs, iPSCs, or adult stem cells that bear an in 87 
vivo tissue-like arrangement, compartmentalization, and functionality. In this review, we adopt 88 
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this definition and will use the term organoids to describe the in vitro cultures of conglomerates 89 
of tissue-specific cells that incorporate cell-cell and cell-matrix interactions in an orderly and 3D 90 
manner. In most cases described here, organoids were cultured either in suspension or embedded 91 
in animal-derived matrices such as Matrigel. Organoids can be generated from clonal derivatives 92 
of adult stem cells or aggregates of stem cells and organ-specific progenitors derived from 93 
primary embryonic cell types, ESCs, or iPSCs. In regular cultures, depending on the types of 94 
organs, organoids can be spherical or irregularly shaped masses ranging in diameter from 0.1 to 95 
1 mm. They demonstrate significant homology in terms of tissue architecture and gene 96 
expression profiles compared to their in vivo counterparts. They also display growth, undergo 97 
morphogenesis, mature, and in many cases, exhibit functionality similar to their tissues of origin 98 
and have the ability to integrate into embryonic and adult tissues upon transplantation.  99 
1.2 MAJOR TRENDS AND CHALLENGES IN CURRENT ORGANOID RESEARCH. 100 
Studies involving organoid generation have rapidly evolved in recent years, branching into a 101 
field going into multiple directions. There are studies using organoids to understand the 102 
pathology of a number of genetic disorders including cystic fibrosis (Dekkers et al., 2013; 103 
Hohwieler et al., 2017), polycystic kidney disease (Freedman et al., 2015), Hirschsprung’s 104 
disease (Workman et al., 2017), and neurodevelopmental defects like microcephaly and 105 
lissencephaly (Bershteyn et al., 2017; Lancaster et al., 2013). Organoid-driven approaches have 106 
been employed to investigate disease mechanisms of infectious pathogens like Helicobacter 107 
(McCracken et al., 2014) and Zika virus (Cugola et al., 2016; Dang et al., 2016; Garcez et al., 108 
2016; Li et al., 2017; Qian et al., 2016). Not surprisingly, organoids derived from intestinal and 109 
hepatic cell types have been examined as a possible source of in vitro tissues for regenerative 110 
medicine, and these studies have been met with great success in numerous animal models 111 
(Fordham et al., 2013; Fukuda et al., 2014; Huch et al., 2015; Takebe et al., 2014; Yui et al., 112 
2012). More recently, toxicology screens (Schwartz et al., 2015; Takasato et al., 2015) and 113 
studies on patient-specific genetic factors and drug responses in tumorigenesis have begun 114 
employing organoid technology (Cristobal et al., 2017; Fujii et al., 2016; Li et al., 2014; Matano 115 
et al., 2015; van de Wetering et al., 2015; Verissimo et al., 2016; Weeber et al., 2015).  116 
ESCs, iPSCs, and, to a certain extent, adult stem cells provide a virtually unlimited 117 
source of raw cellular materials for organoid generation. In the case of ESCs and iPSCs, 118 
organoids are derived either via the embryoid body method, in which pluripotent stem cell 119 
colonies are lifted up from undifferentiated adherent cultures and fragmented into small pieces 120 
for further differentiation (Freedman et al., 2015; Kadoshima et al., 2013; Lancaster and 121 
Knoblich, 2014; Lancaster et al., 2013; Muguruma et al., 2015; Nakano et al., 2012; Suga et al., 122 
2011) or directly from sub-structures formed on differentiating adherent cultures (Calderon-123 
Gierszal and Prins, 2015; Dye et al., 2015; McCracken et al., 2014). Despite these advances in 124 
technique, there are still tissues that are recalcitrant to organoid derivation such as the epidermis, 125 
the testes, the ovaries, the bladder, the thyroid gland, and other non-epithelial tissues such as the 126 
heart and the skeletal muscles (Fatehullah et al., 2016). Additional challenges demand 127 
improvements to current organoid technology. Organoid derivation often results from the tedious 128 
and unguided testing of empirical conditions for proper differentiation, yielding a long and costly 129 
generation process. Heterogeneity in viability, size, and shape of the derived organoids plagues 130 
the development of high throughput systems and algorithms that can be employed for phenotypic, 131 
toxicologic, and drug screens. In many cases, techniques used for generating one type of 132 
organoid cannot be easily transferred to a different organoid system, e.g. the procedures in 133 
developing a brain organoid will bear little resemblance to those for a liver organoid. This lack 134 
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of transferability of organoid techniques across systems hinders the development of the organoid 135 
field and limits its potential to incorporate other fields of study such as computational science 136 
and bioengineering that require the building of mathematical/engineering models and the 137 
incorporation of scalable and cross-system parameters. Importantly, organoids usually lack the 138 
co-induction of the essential cell types and the associated extracellular matrices and native 139 
microenvironment that will allow the recapitulation of the in vivo tissue sizes, structures, 140 
organization, inter-cellular communication, and functionality. Lastly, very little is known about 141 
the culturing conditions and specific factors driving the in vitro maturation of organoids, which 142 
in many cases remain fetal in nature.  143 
1.3 APPLYING THE CONCEPT OF REVERSE ENGINEERING TO ORGANOID 144 
GENERATION. In biology, reverse engineering is the process of extracting the minimal set of 145 
design parameters from existing biological systems for creating a functional mimicry (Ingber, 146 
2016; Shinozawa et al., 2016). Design parameters may include cell type, soluble 147 
microenvironment, insoluble microenvironment, and physical parameters such as shape, external 148 
force, and fluid flow. We propose that by employing the principle of reverse engineering, we can 149 
solve some of these issues, in particular: (i) recapitulating the in vivo cellular heterogeneity in 150 
organoid systems, (ii) controlling the organoid microenvironments including extracellular matrix 151 
(ECM) composition, stiffness, and architecture, and (iii) promoting the in vitro maturation of 152 
organoids. Here, we review current developments and techniques concerning the generation of 153 
human organoids and propose that by studying and employing the minimal elements required for 154 
the different stages of in vitro organoid synthesis and maturation, we can improve and streamline 155 
current organoid generation approaches as depicted in Figure 1.  156 
 157 
2 EXPLOITING THE SELF-ORGANIZING PROPERTY OF EMBRYONIC 158 
PROGENITORS 159 
Self-organization has been widely demonstrated in animal studies, whereby tissue-160 
specific progenitors, after random dispersal, aggregate, sort, and organize to reform a 3D tissue 161 
mass closely resembling the organs and tissues where the cell types belong (Takeichi, 2011). 162 
Recent ESC and iPSC studies have exploited this fundamental cellular principle. Self-163 
organization is a process involving the self-assembly of dissociated cells and the subsequent 164 
reorganization into tissue-like structures. Using this approach, termed “dissociation-aggregation 165 
approach”, cell progenitors from different lineages can be recombined to form in vitro organoids 166 
with improved representation of cellular heterogeneity and interactions. In this section, we 167 
present a historical overview of the discovery of the self-organizing property of animal 168 
progenitors and summarize recent works in human organoids generated based upon this principle. 169 
We also review and propose studies by which the self-organizing process could be monitored 170 
and regulated.  171 
2.1 REGENERATIVE POTENTIAL OF DISSOCIATED CELLS FROM ANIMAL 172 
EMBRYONIC TISSUES AND ORGANS.  173 
2.1.1 Pioneering Experiments in Sponges and Hydroids. In the first series of 174 
experiments conducted over a century ago, Henry van Peters Wilson showed that sponges broken 175 
down into randomly dispersed single cells were able to reorganize into live sponges (Wilson, 176 
1907). Similar results, detailing the generation of live hydranths, were found in a study 177 
performed by Charles Wesley Hargitt (Hargitt, 1915). A similar conclusion was drawn with 178 
some essential differences by a later study performed by De Morgan and Drew using different 179 
species. In their experiments, the resulting tissue aggregates, or restitution mass, developed the 180 
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characterized tissue and cellular architecture of hydranths, e.g. well defined endodermal tubules, 181 
the outer perisarc, and the interstitial ectodermal cells, but soon underwent partial disintegration 182 
and were never able to give rise to live hydranths (De Morgan and Drew, 1914). Despite these 183 
differences, these early experiments sparked enormous interest in the regenerative ability of 184 
animal tissues and clearly demonstrated that dissociated cells carried the potential to reform 185 
tissues and structures. Tissue cells from different cellular origins, e.g. ectoderm and endoderm, 186 
also possessed the ability to attach to one another and undergo cellular rearrangements to achieve 187 
an advanced tissue morphology and architecture resembling those found endogenously. 188 
Interestingly, Wilson also found that cells from different species of sponges sorted out from each 189 
other and only recombined with cells of their own species (Wilson, 1907). This principle is not 190 
strictly adhered to in vertebrate cells where chimeric tissues and organs of different species 191 
origin could quite frequently be generated.  192 
2.1.2 Regenerative Potential of Embryonic Tissues in Other Animal Species. Following 193 
this initial discovery, there remained an important question of whether animal cells generally 194 
possess a similar self-organizing ability. Testing of this hypothesis was not feasible until the 195 
early 1940s when Johannes Holtfreter discovered a way to conveniently dissociate and re-196 
associate Xenopus frog embryonic cells by exploiting the changes in cell adhesion of frog cells to 197 
changes in environmental pH (Steinberg and Gilbert, 2004). Thereafter, Aaron Moscona and 198 
colleagues employed trypsin, at the time a novel enzymatic tool, for more efficient cell 199 
dissociation in avian and mammalian organs and tissues (Moscona, 1957b; Moscona and 200 
Moscona, 1952). Culturing conditions for the resultant tissue aggregates however posed 201 
additional requirements for more finely regulated nutrient and thermal conditions. This led to the 202 
development of more sophisticated culture media and increased precision on the controls for pH 203 
and heating to promote prolonged maintenance of tissue masses in vitro.  204 
Other advances in culturing techniques such as the advent of rotation cultures (Moscona, 205 
1961) and the use of chorioallantoic membrane as an incubator for organoid tissues (Garber and 206 
Moscona, 1964) had facilitated widespread employment of the dissociation-aggregation method 207 
and had advanced cellular differentiation of the resulting organoids. Rotation cultures, for 208 
instance, involved incubation of trypsin-dissociated cell suspension in a swirling flask, assisting 209 
single cells to collide, adhere, and form cell aggregates. It had been used to form mouse 210 
embryonic brain cell aggregates displaying a high degree of cellular organization (DeLong, 211 
1970), undergoing the regular biochemical differentiation and expressing enzymes responsible 212 
for neural transmission (Seeds, 1971), forming myelination of axons and displaying signs of 213 
proliferation and synapse formation (Seeds and Vatter, 1971). Due to concerns that the 214 
aggregative features observed in dissociated embryonic cells was an artificial phenomenon 215 
created by in vitro cultures, a series of studies were carried out aiming to test if dissociated cells 216 
could aggregate in an embryonic environment such as the chorioallantoic membrane. In those 217 
cases, dissociated embryonic kidney, liver, and skin cells were tested and successfully 218 
differentiated as aggregates (Garber et al., 1968; Garber and Moscona, 1964; Weiss and Taylor, 219 
1960). 220 
In another classic embryological experiment, epidermis and neural tube from early 221 
amphibian embryos were dissociated and allowed to re-aggregate (Townes and Holtfreter, 1955). 222 
The two cell populations sorted out from each other and self-organized into epidermal cells 223 
covering the outside of the tissue aggregate containing a neural tube-like structure. Interestingly, 224 
there were other studies producing chimeric organoid structures with different animal species or 225 
even organs with little relation to each other under normal developmental contexts. For instance, 226 
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chimeric experiments were carried out for chick nephrogenic and mouse chondrogenic cells; 227 
ultimately concluding that the nephrogenic and chondrogenic cells aggregate according to their 228 
tissue types, but disregard their species-specificity (Moscona, 1957a). In another study, mouse 229 
skin cells at an advanced stage were found to suppress feather formation in chick-mouse 230 
chimeric aggregates, while mouse skin cells from a younger stage appeared to incorporate into 231 
the feather structures (Garber et al., 1968). Further, chimeric aggregates of human and mouse 232 
cells derived from the same organs (lung, liver, and brain) integrated well with each other— 233 
similar to those derived from the same species—suggesting that, between human and mouse, 234 
tissue specificity dominates over species specificity (Cassiman and Bernfield, 1974). A similar 235 
phenomenon was observed for embryonic chick and rat heart cells, in which chimeric aggregates 236 
were formed (Nag et al., 1980). These experiments highlighted the versatility and flexibility of 237 
the embryonic and fetal progenitors in chimeric species organ synthesis and inspired more recent 238 
experiments that employed the successful integration of embryonic progenitors derived from 239 
ESC and iPSC cultures in animal transplantation as a readout for functionality (e.g. Cohen et al., 240 
2016).  241 
2.1.3 Recent Development Using Dissociated Embryonic Progenitors for Organoid 242 
Generation. Over the past four to five decades, numerous experiments have continuously 243 
demonstrated the tremendous propensity of embryonic and fetal progenitors to self-renew, 244 
differentiate, self-organize, and regenerate. In particular, organoid structures have been generated 245 
from aggregating embryonic and fetal progenitors derived from virtually all types of embryonic 246 
organs and tissues from higher vertebrates including those that are ectoderm (brain, spinal cord, 247 
inner ear, submandibular gland, retina, lens), mesoderm (heart, limb bud, kidney), and endoderm 248 
(lung, pancreas, liver) derived (Table 1). In one particular example, fragments and aggregates of 249 
dissociated cells of embryonic day 13 mouse submandibular gland epithelium were able to self-250 
organize and undergo branching morphogenesis, forming tissues with structural features and 251 
differentiation markers characteristic of the intact gland. The study also reported that the self-252 
organization process was sensitive to perturbation by integrin and E-cadherin signaling (Wei et 253 
al., 2007). In another well-studied example, dissociated embryonic chick retina cells in rotation 254 
cultures were able to reconstitute all the essential retinal layers including differentiating cone and 255 
rod cells aligned in rosette structures within the tissue aggregates. These tissue aggregates, so-256 
called rosette spheres, could reach a size of 0.3-0.5 mm and included up to half a million cells. 257 
The tissue organization of these rosette spheres was further improved by the inclusion of the 258 
retinal pigmented epithelium, which promoted laminar reconstitution and the proper alignment of 259 
the different retinal layers (Layer et al., 2001). Many current studies have shifted their focus 260 
from simple aggregation experiments to a number of different directions including investigating 261 
(1) the identity of the soluble intercellular factors and the intracellular molecular mechanisms 262 
that promote the aggregation and the subsequent cell-sorting processes, (2) the role of 263 
developmental ages of embryonic and fetal progenitors in organoid formation, (3) the effects of 264 
specific dissociation techniques, and (4) the functionality of the resulting tissue aggregates or 265 
organoids with more sophisticated biochemical and morphological studies as readouts for 266 
function. Documenting these studies is out of the scope of this review, but some of them have 267 
been summarized and discussed (Takeichi, 2011). 268 
 269 
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2.2 AGGREGATION EXPERIMENTS EMPLOYING CELL PROGENITORS 270 
DERIVED FROM PLURIPOTENT STEM CELLS.   271 
Given these strong data in animal works and the rich resources of efficient adherent 272 
differentiation protocols, recent studies have started to employ dissociated embryonic cell types 273 
derived from human ESCs and iPSCs as raw materials for organoid generation.  In these studies, 274 
ESC and iPSC colonies were differentiated either directly as colonies or after a re-plating step as 275 
a monolayer of evenly spread-out, single cells. These differentiating adherent cultures, after 276 
reaching the progenitor stages of their respective lineages, were dissociated, dispersed, and re-277 
aggregated to form suspension 3D organoids. In some cases, organoids were derived from 278 
progenitors of single germ layers, like in the case of pancreatic (Hohwieler et al., 2017; Kim et 279 
al., 2016) and kidney organoids (Takasato et al., 2016; Takasato et al., 2015). In other cases, 280 
composite organoids were made from progenitors of multiple germ layer lineages such as liver, 281 
cerebral cortical, and intestinal organoids (Schwartz et al., 2015; Shinozawa et al., 2016; Takebe 282 
et al., 2013; Takebe et al., 2014; Workman et al., 2017). Many of these organoids have been 283 
successfully employed in toxicology studies, disease modeling, and animal transplantation 284 
studies. Timed addition of progenitor cell types to composite organoids has allowed increased 285 
control over the timing and incorporation of specific cell-cell interactions during organoid 286 
generation and differentiation to mimic in vivo situations. Cryopreservation of progenitor cell 287 
types for these organoids has been successfully performed, thus permitting a consistent and 288 
convenient supply of progenitors for organoid formation. 289 
 2.2.1 Organoids Derived from Single Germ Layers. KIDNEY. Mammalian kidneys are 290 
derived from the intermediate mesoderm that gives rise to the major kidney progenitors 291 
including the ureteric epithelium, metanephric mesenchyme, and the renal stroma. Ureteric 292 
epithelium forms the collecting tubes whereas the metanephric mesenchyme forms the nephrons, 293 
which include substructures like the proximal and distal tubules and the glomeruli. The mature 294 
kidney epithelial structures are surrounded by a renal interstitium containing a vascular network 295 
derived from the renal stroma. To generate kidney progenitors, human ESCs were differentiated 296 
from the primitive streak stage to form PAX2+LHX2+ intermediate mesoderm by manipulation 297 
of WNT and FGF signaling (Takasato et al., 2014). Differentiating embryonic kidney cells, 298 
resulting from the further differentiation of PAX2+LHX2+ intermediate mesoderm progenitors, 299 
were dispersed and aggregated to form organoid structures that displayed evidence of 300 
development of the ureteric epithelium, the proximal tubules, and the renal vesicles. However, 301 
no definitive nephron structures could be identified in these organoids. In a subsequent study, by 302 
manipulating the strength and the duration of retinoic acid and WNT signaling, the same group 303 
identified a way to preferentially induce ureteric epithelium development over metanephric 304 
mesenchyme (Takasato et al., 2016; Takasato et al., 2015). By dissociating progenitors at an 305 
earlier time point (day 6 instead of day 18) and optimizing WNT and FGF signaling post-306 
organoid formation, kidney organoids matured to form nephron-like structures including the 307 
essential components of collecting ducts, distal and proximal tubules, and glomeruli. Endothelial 308 
vascular networks, together with pericyte-like and mesangial-like cells, were also identified and 309 
appeared to invade some of the glomeruli. Advanced morphological patterning in terms of the 310 
arrangement of the collecting ducts to nephron-like structures and the presence of cortical versus 311 
medullary stroma patterning indicated the formation of a complex kidney-like structure. 312 
Furthermore, these organoids were tested positive for endocytic function to dextran and for 313 
response to nephrotoxic agents like Cisplatin. Comparisons to a range of human fetal tissues 314 
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suggested that these kidney organoids resembled first trimester kidney tissues suggestive of their 315 
fetal nature and the need for further maturation.   316 
 PANCREAS. The pancreas is a glandular organ, which serves dual functions in 317 
regulating blood sugar level, by its exocrine glands that secrete insulin and glucagon and in 318 
digesting proteins, lipids, carbohydrate, and nucleic acids by excreting enzymes from its 319 
endocrine glands. Exocrine (Hohwieler et al., 2017) and endocrine (Kim et al., 2016) pancreatic 320 
progenitors have been respectively derived from human ESC and iPSC 2D cultures. These 321 
cultures were dissociated and re-aggregated in suspension to form functional and transplantable 322 
endocrine and exocrine organoids. Both endocrine and exocrine pancreatic progenitors were 323 
differentiated from ESCs and iPSCs via activation of WNT and Activin signaling to prompt a 324 
definitive endoderm fate, followed by treatment with retinoid acid, FGF ligand, and BMP 325 
inhibitor to generate PDX1+ pancreatic endoderm, a common progenitor for endocrine and 326 
exocrine cell types. PDX1+ cells were then skewed towards either exocrine or endocrine 327 
progenitors using distinct growth factor and small molecule cocktails.  328 
Pancreatic endocrine cells expressed proprotein convertase 1/3, glucose transporter 1, and 329 
the majority of pancreatic hormones such as insulin, somatostatin, and pancreatic peptide, with 330 
the exception of glucagon (Kim et al., 2016). Detailed marker profiling, however, suggested that 331 
these endocrine cells were still immature. For instance, the authors observed a low expression 332 
level of mature β-cell marker NKX6-1 and the coexpression of endocrine progenitor marker 333 
MAFB with insulin, indicating that the endocrine cells derived were immature. Upon organoid 334 
formation by aggregation of endocrine cells, these cells continued to express pancreatic 335 
hormones and the above mentioned functional markers, but, in addition, lost expression of 336 
MAFB in insulin+ cells, gained expression of the mature -cell marker MAFA (Nishimura et al., 337 
2006), and increased expression of glucose sensor genes (SLC2A1 and GCK). All these were 338 
indicative of improved -cell function and maturation. Further, these pancreatic endocrine 339 
organoids displayed sensitivity to high glucose concentration and responded by inducing insulin 340 
and c-peptide secretion. Functionally, transplantation of pancreatic endocrine organoids 341 
prolonged the life span of streptozotocin treated mice, which had their pancreatic islet destroyed 342 
by streptozotocin treatment. The mice with organoid transplants displayed a response to high 343 
blood glucose and expressed at least one endocrine hormone, c-peptide, in the blood stream. 344 
Function of the transplants however gradually became unstable after 2 weeks. Mice survived 345 
more than 40 days, but a more long-term survival study was not conducted and ultimate cause of 346 
transplant failure was not concluded.  347 
In contrast to endocrine organoids, human pancreatic exocrine organoids formed by 348 
aggregation of dissociated exocrine cells contained acinar-like and ductal-like cell types and 349 
structures (Hohwieler et al., 2017). Activities for key exocrine enzymes such as carbonic 350 
anhydrase, amylase, trypsin, and elastase were detected. Cystic fibrosis patients display 351 
increased probability of pancreatitis, pancreatic exocrine insufficiency, and pancreatic cancer. 352 
Patient iPSCs carrying CFTRa mutations were used to derive pancreatic exocrine organoids for 353 
modeling cystic fibrosis disease progression. Forskolin is known to induce rapid swelling of 354 
control intestinal organoids but not in organoids derived from a cystic fibrosis mouse model 355 
 
aCystic fibrosis transmembrane conductance regulator (CFTR), the gene mutated in cystic fibrosis, 
encodes a chloride channel protein, a member of ATP-binding cassette transporter superfamily. CFTR 
mediates fluid homeostasis in the epithelia of organs such as pancreas, liver, intestine, and lung.  
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(Dekkers et al., 2013). Expectedly, forskolin/IBMX treatmentb did not induce much swelling in 356 
the lumens of human cystic fibrosis patient-derived organoids. Encouragingly, the swelling 357 
defect could be ameliorated in a pre-selected set of CFTR correctors and potentiators with known 358 
functions in improving CFTR activity, or with chemically modified CFTR mRNA that confers 359 
high stability and low immunogenicity, demonstrating a proof of principle for these organoids in 360 
disease modeling and compound screening. However, upon orthotopic transplantation to a mouse 361 
host, the human organoids remained fetal in gene expression, and, because of a lack of functional 362 
assays, it was difficult to assess the maturity and purity of the resulting human grafts.  363 
 2.2.2 Germ Layer Composite Organoids. INTESTINAL SYSTEM. Attention has often 364 
been paid to parenchymal cells in organoid generation. The role of non-parenchymal cells, such 365 
as neural cells, mesenchymal cells, and vascular cells, has been well documented in development 366 
and tissue functionality (Cleaver and Melton, 2003; Furness, 2012). A recent study, which 367 
appreciates the inclusion of these non-parenchymal cell types, generated human intestinal 368 
organoids with an intact enteric nervous system (Workman et al., 2017). In this study, 369 
dissociated caudal neural crest cells were recombined with human intestinal organoids by low 370 
speed centrifugation. Neuronal and glial differentiation was observed in intestinal organoids 371 
seeded with neural crest cells. The overall spatial relationship of the resulting composite 372 
organoid resembled human fetal or mouse embryonic day 11.5 intestine. These organoids were 373 
cultured in vitro for 28 days before transplantation. Importantly, the graft displayed neuronal 374 
calcium oscillations, contractile activity, and neuromuscular coupling suggestive of a functional 375 
enteric nervous system. These grafts were also used to model the phenotype of PHOX2B 376 
mutations in the etiology of Hirschsprung’s disease, a genetic disorder resulting in 377 
agangliogenesis of the human bowel.    378 
 LIVER. Hepatocytes are the major cell type in the liver, which make up around 80% of 379 
the parenchymal mass in the adult organ and display both endocrine and exocrine properties (Si-380 
Tayeb et al., 2010; Zhao and Duncan, 2005). Non-hepatocyte cell types such as cholangiocytes, 381 
sinusoidal endothelial cells, Ito cells (hepatic stellate cells), Kupffer cells (tissue macrophages), 382 
and pit cells (natural killer cells) constitute the rest of the liver. The liver buds, which are derived 383 
from the foregut endoderm and containing the adult liver progenitors, are formed around 384 
embryonic day 8.5 in mouse. At embryonic day 9.5, hepatoblasts delaminate from the liver buds 385 
to invade the surrounding septum transversum (mesoderm derived), which contains progenitors 386 
for non-hepatocyte cell types such as Ito cells and endothelial cells. To recapitulate the in vivo 387 
cellular heterogeneity of adult liver and to promote the vascularization that is essential for 388 
normal liver function and transplantation, Takebe et al. attempted to generate in vitro human 389 
liver buds by aggregating cell types from two germ layer lineages: hepatic endoderm derived 390 
from ESC/iPSC cultures, and from the mesoderm, umbilical vein endothelial cells and 391 
mesenchymal stem cells (Takebe et al., 2013; Takebe et al., 2014). A 10: 7: 2 ratio of human 392 
HNF4A+ hepatic endoderm, umbilical vein endothelial cells, and mesenchymal stem cells were 393 
mixed and resuspended in hepatocyte culture medium. The cells in the suspension aggregated 394 
and self-organized to form liver-bud organoids containing an endothelial network and maturing 395 
hepatocytes with increased expression of early liver specific genes like alpha-fetoprotein, retinol 396 
binding protein 4, transthyretin, and albumin. Microarray analyses suggest that the resulting 397 
 
b Forskolin increases the amount of intracellular cAMP, which in turn activates CFTR that mediates fluid 
secretion into the lumen of small intestinal organoids. IBMX (3-isobutyl-1-methylxanthine) is a 
phosphodiesterase inhibitor. Because of its effect in inhibiting phosphodiesterase, IBMX may potentiate 
the accumulation of intracellular cAMP by the action of forskolin. 
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liver-bud organoids resembled early embryonic liver buds in mouse (embryonic day 10.5 to 398 
11.5). Upon transplantation into mouse brain, connectivity with host vasculatures was quickly 399 
observed. Prolonged cultures of transplants up to 60 days led to development of hepatic cord-like 400 
structures, which contained cells expressing tight junction proteins and collagens that are 401 
normally found along the entire length of the liver sinusoids. Albumin production by day 45 of 402 
transplantation was comparable to or surpassed in vitro cultures of adult human hepatocytes. 403 
Ketoprofenc and debrisoquined were used to distinguish human hepatic metabolic functions from 404 
mouse hepatic functions since these drugs are metabolized differently in human and mouse livers. 405 
Human specific metabolites, upon challenge with ketoprofen or debrisoquine, were found in the 406 
transplanted mouse blood serum and urine, suggestive of the presence of functional human liver 407 
tissues in the organoids. An additional minimally-invasive mesenteric transplantation model was 408 
carried out and the transplanted liver buds promoted survival of mice with ganciclovir-induced 409 
liver failure by ~50% at day 30 after transplantation. No specific markers or assays however 410 
were used to detect the presence of other non-hepatocyte cell types either under in vitro cultures 411 
or upon transplantation. These non-hepatocyte cell types play important roles in liver function 412 
and pathology. Cholangiocytes, for example, are important for bile metabolism and hepatocyte 413 
survival and have been successfully derived from human iPSC cultures (Dianat et al., 2014). For 414 
other non-hepatocyte cell types, such as pit cells and Kupffer cells, there are no existing 415 
differentiation protocols. 416 
CENTRAL NERVOUS SYSTEM. To mimic in vivo brain development, neural 417 
constructs (organoids) were generated by aggregating dissociated neural progenitors, 418 
mesenchymal stem cells, endothelial cells, and microglial/macrophage precursors (Schwartz et 419 
al., 2015). Neural constructs were formed with neural progenitors embedded in polyethylene 420 
glycol hydrogels, followed by seeding of endothelial cells and mesenchymal stem cells at day 9 421 
and lastly with microglial/macrophage precursors at day 13 to mimic the in vivo recruiting 422 
sequence of blood vessels and macrophage after the formation of the neural tube. Timed addition 423 
of cell precursors to the initial neural constructs allowed temporal control of the incorporation of 424 
different cell types. The resultant neural organoids bore gene signatures for forebrain and 425 
hindbrain development and displayed markers for GABAnergic neurons, glutamatergic neurons, 426 
and glia. Extensive vascular networks and phagocytic activities were observed in the neural 427 
organoids suggestive of functional vascular and macrophage cell types. Machine learning refers 428 
to studying and developing algorithms that can iteratively learn from data without being 429 
explicitly programmed and make predictions. The neural organoids were employed for machine 430 
learning using RNA sequencing datasets with known neurotoxins and control compounds. 431 
Subsequent blind trials found that toxicity of 9 out of 10 known compounds could be correctly 432 
predicted suggesting that such neural organoids could be used for in vitro drug toxicity screens, 433 
although the authors admitted that a functional perfused blood-brain barrier could further 434 
improve predictability of drug toxicity. The blood-brain barrier is lined by specialized 435 
endothelial cells, called brain microvascular endothelial cells that regulate the transport of 436 
substances into and out of the brain. To reconstruct a functional adult-like blood-brain barrier, 437 
additional cell types are required, such as pericytes and brain microvascular endothelial cells 438 
 
c Ketoprofen is primarily metabolized to ketoprofen-glucuronide by human hepatocytes and metabolized 
to hydroxyl-ketoprofen by mouse hepatocytes. 
d Debrisoquine is metabolized to 4-hydroxy debrisoquine by CYP2D6 in human hepatocytes. Mouse liver 
lacks 4-hydroxylase activity and thus cannot convert debrisoquine into its 4-hydroxy metabolite. 
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(Lippmann et al., 2013). These cell types have been derived from human ESC and iPSC cultures 439 
(Lippmann et al., 2012; Orlova et al., 2014).  440 
2.2.3 Monitoring and Regulating the Self-organization Process to Facilitate Organoid 441 
Formation. We envisage more widespread usage of the dissociation-aggregation method in 442 
future studies, especially for organ systems whose full functionality depends on the incorporation 443 
of multiple germ layer lineages. To improve this method, we propose timed and sequential 444 
incorporation of tissue- and organ-specific cell progenitors to better mimic the events occurring 445 
during embryonic development (Figure 2). Self-organization of the aggregating cells during 446 
organoid formation can be broken down into steps of temporally-overlapping and interrelated 447 
processes that could be monitored and regulated. These include the chemotactic movement of the 448 
aggregating cells (Chen et al., 2007), the cell surface interactions to matrices and to neighboring 449 
cells (Takebe et al., 2015), the cell-sorting process, the formation of the apical-basal orientation 450 
of individual cells, and the process of lumenogenesis (Odenwald et al., 2017; Taniguchi et al., 451 
2015) (Figure 3). Time-lapse imaging of aggregating cell populations labeled transiently with 452 
fluorescent dyes or permanently with genetically-engineered reporters could allow tracking of 453 
the kinetics of organoid formation, whether they form under certain conditions or not, and, if 454 
they do form, how fast they form, and the dynamic changes of their shape along the time course 455 
of their formation. The speed of condensation and the changes in the shape of the forming 456 
organoids could be monitored by quantitative analyses (Takebe et al., 2015). Additionally, 457 
pharmacological interventions can be applied to regulate the speed of aggregation. Takebe et al. 458 
found that manipulation of myosin II activity controlled the collective movement of cells during 459 
the aggregation process (Takebe et al., 2015). Mesenchymal stem cells within the initial 460 
aggregating mix were identified as a key cell population that was essential to drive the 461 
aggregating process (Takebe et al., 2015). By closely monitoring the structural parameters of the 462 
forming organoids, such as their diameter and morphology, Arora and colleagues were able to 463 
promote the yield of successful intestinal organoids using an automated micro-peptide aspiration 464 
and release system (Arora et al., 2017). More studies in these areas are urgently needed to 465 
translate findings from organoid monitoring into promoting the successful formation of 466 
organoids.   467 
 468 
3 UTILIZING DESIGNER MATRICES AND SCAFFOLDS FOR ORGANOID 469 
FORMATION 470 
3.1 DESIGNER MATRICES AND MATRIX PARAMETERS. When considering the 471 
minimal elements for forming a functional organ or tissue, one must consider not only 472 
parenchymal cells and the less-represented and essential cell types like immune, vascular, and 473 
neural cells, but also the secreted ECM framework and its associated growth factors, cell 474 
interacting molecules, enzymes, and extracellular vesicles that produce the necessary physical 475 
and biochemical signals to support organ and tissue maintenance, growth, and morphogenesis. 476 
To mimic the physical and biochemical properties of in vivo cellular microenvironment, designer 477 
matrices (Gjorevski et al., 2014), either derived from natural sources or artificially synthesized 478 
with physical and biochemical properties specially designed for a certain cell type can be 479 
employed. Controls exercising on organoid formation can be greatly facilitated by incorporating 480 
designer matrices. For example, micropores present in hydrogels and scaffolds would allow 481 
organoid formation at a defined shape and size. The physical and biochemical properties of 482 
designer matrices can be spatially and/or temporally controlled to enable stem cells to self-483 
organize, and this topic has been elegantly reviewed (Gjorevski et al., 2014). Together with 484 
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advanced 3D printing technology, studies can be conducted to fabricate designer matrices with 485 
controlled nano- and micro-structures to standardize and improve organoid formation. We 486 
propose that by studying the endogenous composition and dynamics of ECM expression during 487 
the development of animal and human organs and tissues and empirically testing the 488 
requirements of these ECM and other tailor-made matrices in in vitro cultures, one would be able 489 
to determine the minimal and essential elements and signals from the ECM that are required for 490 
the cellular activity, organization, and differentiation of organoid cultures.  491 
A number of parameters dictate the ability of matrices to modulate organoid formation. 492 
These parameters include stiffness, composition, topology (or geometry), degradability, the 493 
ability to bind growth factors, and the capacity to modulate growth factor activities. Regulating 494 
these parameters may prove advantageous to promoting organoid formation, standardizing 495 
organoid production, and moving organoid technology to clinics. Organoids are currently 496 
cultured either matrix-free or by embedding them in matrices like Matrigel. Matrix-free 497 
suspension organoid cultures display superb nutrient diffusion, but lack certain physicochemical 498 
supports, resulting in organoids that may clump and causing lower yields, and may develop 499 
necrosis within the core. Matrix provides an initial guidance to the aggregating cells and serves 500 
as a subsequent physical support and constraint for organoid formation. Matrigel and collagen 501 
type I are the most commonly used matrices in organoid cultures derived from ESCs, iPSCs, and 502 
adult stem cells. However, there are few studies investigating the precise roles of these matrices 503 
in supporting organoid formation. On top of this, the animal origin and lot-to-lot variation of 504 
Matrigel hinders the use of the derived organoids in clinical applications. Fully synthetic or 505 
recombinant matrices are chemically defined and can be standardized for organoid production 506 
and better facilitate downstream clinical applications. Well-defined matrices, such as those 507 
incorporating synthetic ECM peptides with artificial hydrogels, allow precise control of the 508 
cellular microenvironments.  509 
Matrix stiffness is an important parameter regulating cell behavior. Matrix stiffness 510 
reflects the resistance that a cell experiences when it deforms the matrix, and it can be measured 511 
by the elastic constant (Young’s modulus, presented as Pascal). Cells sense matrix stiffness 512 
through mechanoreceptors, such as integrins (Humphrey et al., 2014). It was found that a stiffer 513 
hydrogel (1.3 kPa) supported intestinal stem cell expansion, whereas softer hydrogel 514 
(approximately 190 Pa) promoted differentiation and intestinal organoid formation, suggestive of 515 
a role played by matrix stiffness in regulating cell proliferation versus differentiation in 3D 516 
environments (Gjorevski et al., 2016). Earlier studies also revealed an important function of 517 
matrix stiffness in lineage specification of mesenchymal stem cells in 2D (Engler et al., 2006) 518 
and 3D environments (Huebsch et al., 2010) and ESCs in 2D environments (Chowdhury et al., 519 
2010). As a prime example, precise temporal control of matrix stiffness can be achieved by 520 
synthesizing a composite with specific proportions of degradable and non-degradable synthetic 521 
hydrogels, thus providing additional guidance to stem cell renewal and differentiation as shown 522 
in intestinal organoid cultures (Gjorevski et al., 2016).  523 
3.2 CHARACTERIZATION OF ECM IN IN VITRO CULTURES AND DURING 524 
DEVELOPMENT. ECM composition and architecture is under constant remodeling during 525 
normal development (Daley et al., 2008) and ESC differentiation. Data from human embryonic 526 
liver development demonstrated dynamic expression pattern of integrins and ECM components 527 
(Couvelard et al., 1998). During embryoid body formation from human ESCs, the expression of 528 
fibronectin was spatiotemporally correlated with the expression of a definitive endoderm marker 529 
GATA4 (Taylor-Weiner et al., 2013). A reverse correlation was found with the expression of a 530 
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pluripotent marker NANOG. Directed differentiation of ESCs to definitive endoderm produced 531 
fibrillar fibronectin whereas other lineage differentiation or ESC cultures produced punctate 532 
fibronectin. Kanninen et al. have recently discovered that integrin expression was dynamic 533 
during hepatic differentiation of human ESCs and iPSCs (Kanninen et al., 2016). The expression 534 
of laminin-511/521-specific integrins increased during definitive endoderm induction and 535 
hepatic specification. They showed that laminin-511 and laminin-521 promoted hepatic 536 
specification from human definitive endoderm cells (Kanninen et al., 2016). Recombinant 537 
laminin-511 and laminin-521 would presumably provide an optimal biochemical cue as a 538 
designer matrix to assist generation of liver organoids.  539 
To understand the dynamic changes in ECM, temporal expression studies need to be 540 
carried out to examine the changes in ECM molecule expression during consecutive 541 
developmental stages. Studying the secretome of a cell population that includes growth factors, 542 
extracellular matrices, extracellular proteinases, and enzymes may prove to be extremely useful. 543 
For example, transcriptomic analyses have been performed to determine the changes in 544 
secretome across several early kidney developmental stages (Martinez et al., 2006). More 545 
advanced technology involving the use of automated and high-throughput tandem mass 546 
spectrometry (MS) can be employed to identify the secretome and the proteome of the ECM of 547 
cultured cells under various experimental conditions and of in vivo tissues across developmental 548 
stages (Byron et al., 2013; Ngounou Wetie et al., 2013). Steps such as sample or peptide 549 
fractionation and liquid chromatography (LC) prior to MS can help reduce sample complexity 550 
and ease the identification of ECM components. Such approaches had been successfully used to 551 
identify tens to hundreds of ECM components from tissues ranging from eyes to mammary 552 
glands to cartilages (Byron et al., 2013). Solid-state NMR spectroscopy and matrix-assisted laser 553 
desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) have been suggested 554 
for the compositional analysis of natural ECM and bioengineered tissues (Schiller and Huster, 555 
2012). Low abundant proteins can be detected directly with high-resolution MS or a coupled LC 556 
and LC-MS/MS system (i.e. ESI-Q-TOF MS, FT-ICR-MS) (Personal communication with Dr. 557 
Andrzej Ciechanowicz). To investigate a more dynamic biological system, as occurs in 558 
development, quantification of the relative or absolute amount of particular ECM and secretome 559 
components can be achieved by MS using isotope labeling or other label-free strategies. Key 560 
ECM and secreted biologically-active protein components identified from secretome assay could 561 
be tested for functionality in promoting organoid formation and development via loss-of-function 562 
experiments or ectopic administration. Recently, an ECM array platform has been developed to 563 
empirically examine the composition of ECM molecules permissive for definitive endoderm 564 
differentiation towards the liver and pancreatic lineages (Braga Malta et al., 2016). Coupling 565 
array studies with the protein expression data from MS assays will provide valuable information 566 
for formulating designer matrices in organoid formation.  567 
3.3 APPLICATIONS OF DESIGNER MATRICES. To incorporate the dynamic 568 
changes in ECM composition into organoid differentiation protocols, one may passage 569 
dissociated organoid cells at defined time points onto predesigned matrices and scaffolds or may 570 
incorporate relevant ECM components into a bio-inert scaffold or hydrogel with degradable 571 
matrices, as described previously (Gjorevski et al., 2016). The same study found that a synthetic 572 
hydrogel, polyethylene glycol, did not support organoid formation (Gjorevski et al., 2016). 573 
Polyethylene glycol cannot interact with cells; it only provides physical support. This finding 574 
indicates that additional biochemical signals generated by the biologically-active matrices were 575 
critical for organoid formation. Biologically-active matrices can generate signals either by 576 
 15
directly interacting with cell membrane receptors such as integrins or by binding to growth 577 
factors. Many ECM components have integrin-binding domains and/or growth-factor-binding 578 
domains, which can be incorporated into designer matrices. It is well-known that the ECM binds 579 
and influences the activities of growth factors (Rozario and DeSimone, 2010). More 580 
sophisticated design of matrices can be used to create concentration gradients of growth factors, 581 
thereby guiding morphogenetic events. Growth factors can also be conjugated on matrices to 582 
sustain their releases to cells during prolonged organoid cultures (Lutolf and Hubbell, 2005). 583 
To achieve endogenous matrix architecture, a recent study used multi-photon excited 3D 584 
printing technology to produce an ECM scaffold that mimics the developing mouse heart tissues 585 
with submicron resolution (Gao et al., 2017). The scaffold was seeded with component cell types 586 
of developing heart derived from human ESC and iPSC, such as cardiomyocytes, endothelial 587 
cells, and smooth muscle cells. The resultant so-called cardiac muscle patches, although much 588 
smaller in size than regular organoids, tested positive for cell engraftment and increased cardiac 589 
function in a mouse model for cardiac infarction. In this study, however, only fibronectin was 590 
used. Incorporation of multiple relevant ECM molecules mimicking the endogenous composition 591 
of ECM in the heart and other organ systems will enhance the applicability of this 3D scaffold 592 
printing technology.   593 
Collectively we propose that designer matrices fabricated based on the understanding of 594 
the dynamic changes in ECM parameters during in vivo organ and tissue development and robust 595 
empirical testing could maximize the self-organizing capacity of cells and provide an optimal 596 
environment for human organoid formation.  597 
 598 
4 PROMOTING THE MATURATION OF ORGANOIDS 599 
In vitro organoid cultures have thus far failed to produce fully-mature cell types. 600 
Intestinal, gastric, lung, kidney, and cerebral organoids derived from human ESCs and iPSCs 601 
exhibit immature phenotypes, resembling human fetal organs (Camp et al., 2015; Dye et al., 602 
2015; Finkbeiner et al., 2015; Hohwieler et al., 2017; McCracken et al., 2014; Takasato et al., 603 
2015). To promote the maturation of in vitro-derived organoids, maturation factors need to be 604 
introduced and culturing conditions must be adjusted at subsequent stages of differentiation to 605 
drive the transition of fetal organoids into more adult-like phenotype. Narrowly, “maturation 606 
factors” could refer to proteins or chemical factors secreted from cells that promote the 607 
maturation of fetal tissues towards more adult-like tissues. In a broader sense, they could refer 608 
broadly to factors ranging from cell-cell interacting factors, circulating hormones, microbial-609 
derived factors (Avior et al., 2015), electrical signals to other unknown factors that could 610 
promote the same process for specific cell types. There is ongoing debate on how maturation of 611 
embryonic tissues is achieved. One hypothesis suggests that tissue maturation is driven by the 612 
induction of adult stem cells in fetal tissues. An alternative hypothesis suggests that authentic 613 
tissue-specific fetal stem cells, distinct from adult stem cells, exist during development and 614 
contribute to tissue maturation. In this section, we review studies and propose a number of 615 
approaches with which maturation of organoids could potentially be achieved. Furthermore, we 616 
review current studies that attempt to promote the in vitro maturation of organoids with variable 617 
successes.   618 
4.1 ORGANOID MATURATION UPON TRANSPLANTATION. There are concerns 619 
that organoids derived from human ESC and iPSC, even after prolonged cultures, might be 620 
unable to mature in vitro to become adult-like tissues. However, that transplantation into animal 621 
tissues in many cases induces maturation of human organoids (Cho et al., 2017; Finkbeiner et al., 622 
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2015; Takebe et al., 2013; Watson et al., 2014; Workman et al., 2017) suggests that functional 623 
maturation of in vitro organoids could be achieved. For instance, transplantation into the kidney 624 
capsule of mice promoted the maturation of both the intestinal and the enteric nervous system of 625 
human intestinal organoids (with neural crest-derived enteric neurons) after engraftment for 6 to 626 
10 weeks (Workman et al., 2017). Highly mature intestinal tissues, with villi and crypts 627 
containing functional intestinal stem cells, were formed in vivo. Enteric neurons and glia 628 
were organized into ganglionic structures in close proximity to the submucosal and myenteric 629 
layers of smooth muscle fibers. Nitric oxide synthase expression was detected upon 630 
transplantation, another sign of maturation of the enteric nervous system. One possible 631 
explanation is that vascularization of organoid structures brings in by the blood stream active 632 
components like hormones and serum proteins that could assist a general tissue maturation 633 
process. This notion is supported by the enhanced maturation of human intestinal and liver 634 
organoids upon ectopic transplantation into adult tissue sites away from their organs of origin, 635 
such as to kidney capsule and brain respectively when compared with in vitro cultured organoids 636 
(Finkbeiner et al., 2015; Takebe et al., 2013). Another possibility is that this transplantation-637 
induced maturation could be due to the direct contact of immature organoid cell types with an 638 
adult environment. For instance, adult stem cell niche factors, present in the in vivo tissues, may 639 
play a role during the maturation process (section 4.2).  640 
4.2 ADULT STEM CELL NICHE FACTORS AS POTENTIAL MATURATION 641 
FACTORS. Adult stem cells (also called tissue stem cells) reside in a tissue-specific 642 
environment, called the stem cell niche. A stem cell niche maintains the self-renewal of adult 643 
stem cells and is comprised of ECM, soluble factors, and in some cases niche support cells 644 
(Rojas-Rios and Gonzalez-Reyes, 2014). Organoids have been derived from adult stem cell-645 
containing tissues, such as the intestinal crypts (Sato et al., 2009), the colonic crypts (Sato et al., 646 
2011), the gastric glands (Barker et al., 2010; Bartfeld et al., 2015), the biliary ducts (Huch et al., 647 
2013b), and the pancreatic ducts (Boj et al., 2015; Huch et al., 2013a). To demonstrate the self-648 
renewal and multipotency of adult stem cells, organoids have also been clonally derived from 649 
single proliferative adult stem cells isolated from a number of mouse and human organs and 650 
tissues including the small intestines (Sato et al., 2009), the colons (Sato et al., 2011), the gastric 651 
pyloric glands (Barker et al., 2010), the gastric corpus tissues (Bartfeld et al., 2015), the 652 
pancreatic ducts (Huch et al., 2013a), the biliary ducts (Huch et al., 2013b), the liver (Huch et al., 653 
2015), the lungs (Kumar et al., 2011; McQualter et al., 2010), the prostate gland (Chua et al., 654 
2014; Karthaus et al., 2014), the mammary glands (Jamieson et al., 2016; Shackleton et al., 655 
2006), the salivary glands (Nanduri et al., 2014), the retina (Tropepe et al., 2000), and the 656 
fallopian tubes (Kessler et al., 2015). Adult stem cell-derived organoid structures were formed 657 
either via the curling up of adult stem cell-containing tissue fragments or via cell division of 658 
single stem cells into closed cyst-like structures. Most of the clonally derived adult stem cell 659 
organoids were embedded within laminin-rich Matrigel and comprised only of epithelial cells 660 
without the presence of stromal and mesenchymal cell types. In rare cases when intestinal tissue 661 
fragments that contained stroma were cultured, the derived organoids would consist of polarized 662 
epithelial cells surrounded by myofibroblasts and the epithelial compartment developed both 663 
crypt-like structures and villus-like protrusions into the lumens (Ootani et al., 2009). Adult stem 664 
cell-derived gastric organoids showed higher expression of differentiated markers for glandular 665 
cell types such as mucous neck, chief or endocrine cells (Muc6, Pgc, Gif, Chga, Chgb, Sst, and 666 
Gast) (Fernandez Vallone et al., 2016). Transcriptomes of organoids derived from adult stem 667 
cells clustered with their corresponding adult cells based on gene expression profiling studies. 668 
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While global gene expression profiling by RNA sequencing revealed that human gastric 669 
organoids derived from human ESCs/iPSCs resembled human fetal instead of adult stomach 670 
tissues (McCracken et al., 2014). There is no single study to our knowledge that has directly 671 
compared the transcriptomes of organoids derived from human ESCs/iPSCs and adult stem cells. 672 
Adult stem cell-derived organoids are cultured in conditions that attempt to mimic the 673 
paracrine signals and the ECM components provided by their corresponding stem cell niches. 674 
Identification of these culturing parameters and conditions may prove beneficial in identifying 675 
cues to control the expansion and maturation of organoids derived from human ESCs and iPSCs. 676 
The commonly used niche factors in mouse intestinal organoid cultures are EGF, Noggin, and R-677 
spondin 1 (abbreviated as ENR condition). ENR condition was sufficient to maintain mouse 678 
intestinal stem cell self-renewal and promoted differentiation to all intestinal epithelial lineages. 679 
To further promote self-renewal and suppress differentiation of stem cells, two small molecules, 680 
a glycogen synthase kinase 3β inhibitor CHIR 99021 and a histone deacetylase inhibitor valproic 681 
acid, have been employed (Yin et al., 2014). Under this condition, morphology of organoids 682 
became homogenous and formed elongated crypt (budding) structures. Intestinal stem cells 683 
(Lgr5-GFP) were also found throughout the organoids. In contrast, manipulation of Wnt and 684 
Notch signaling directed differentiation of organoids into specific lineages such as enterocytes, 685 
goblet cells or Paneth cells (Yin et al., 2014).  686 
Other types of adult stem cell organoids required not only the ENR condition but also 687 
additional factors for self-renewal and growth. Some of these additional factors may suppress 688 
differentiation. For example, on top of ENR, mouse colon organoid cultures required exogenous 689 
Wnt3A (Sato et al., 2011); human intestinal and colon organoid cultures Wnt3A, gastrin, 690 
nicotinamide, a TGFβ inhibitor A-83-01, and a p38 inhibitor SB202190 (Sato et al., 2011); 691 
mouse gastric organoid cultures Wnt3A and FGF10 (Barker et al., 2010); and human gastric 692 
organoids Wnt, gastrin, FGF10, and A-83-01 (Bartfeld et al., 2015). To induce or control the rate 693 
of differentiation, some of the niche factors were removed or their concentrations adjusted. 694 
Mouse colon organoids and human intestinal and colon organoids under growth conditions did 695 
not produce differentiated cells. To induce differentiation, Wnt3A, A-83-01, and SB202190 696 
needed to be withdrawn (Sato et al., 2011). Also, mouse gastric organoids under growth 697 
condition expressed gastric epithelial markers but lacked markers of pit and enteroendocrine 698 
lineages (Barker et al., 2010). Reduction in Wnt3A concentration resulted in the formation of pit 699 
cells, mucus neck cells, and enteroendocrine cells. Differentiation of human gastric organoids 700 
could be controlled by addition of nicotinamide for gland-type organoids and withdrawal of Wnt 701 
for pit-type organoids (Bartfeld et al., 2015).  702 
In the normal adult liver, stem cells have been identified in the pericentral (Wang et al., 703 
2015) and periportal regions (Miyajima et al., 2014). These stem cells can give rise to both 704 
hepatocytes and biliary epithelial cells (cholangiocytes). EPCAM is a marker for these liver stem 705 
cells (Schmelzer et al., 2007). EPCAM+ cells from bile ducts of adult human liver produced 706 
organoids in the presence of EGF, R-spondin 1, FGF10, nicotinamide, HGF, a TGFβ inhibitor A-707 
83-01, and a cAMP pathway agonist Forskolin (Huch et al., 2015). In vitro hepatocyte 708 
differentiation of the organoids required BMP7 treatment followed by the withdrawal of R-709 
spondin 1, FGF10, nicotinamide, and Forskolin and the addition of FGF19, DAPT, and 710 
dexamethasone. The resulting cells exhibited hepatocyte morphology, expressed high levels of 711 
hepatocyte markers and performed liver functions, such as albumin secretion, CYP3A4 activity, 712 
LDL uptake, glycogen storage, bile acid salt secretion, and ammonia detoxification. Upon 713 
transplantation, human liver organoid cells also became hepatocyte-like cells and produced 714 
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human albumin, though the level was lower than that produced by transplanted primary human 715 
hepatocytes.  716 
Pancreatic ductal organoids have been generated from duct fragments or ductal cells of 717 
normal mouse pancreas using ENR, FGF10, nicotinamide, and gastrin; human pancreatic 718 
organoids additionally required Wnt3A, A-83-01, and prostaglandin E2 (Boj et al., 2015; Huch 719 
et al., 2013a). These organoids exhibited budding structures with an enriched ductal cell 720 
population, but they were devoid of acinar and endocrine lineages (Boj et al., 2015). Following 721 
orthotopic transplantation into the tail region of the mouse pancreas, both mouse and human 722 
organoids developed ductal structures evidenced by the expression of CK19, but the presence of 723 
other lineages was not reported (Boj et al., 2015).  724 
Regeneration of ectoderm-derived tissues has enormous value in treatments of 725 
degenerative diseases such as age-related macular degeneration and Alzheimer’s disease. By 726 
colony-forming assay, retinal stem cells were identified from the ciliary margin in the adult 727 
mouse eye (Tropepe et al., 2000). These cells were pigmented cells that could clonally 728 
proliferate and give rise to spheres in vitro. FGF2 signaling promoted their proliferation and 729 
colony forming ability. A single pigmented cell from the ciliary margin generated in 7 days a 730 
large sphere consisting of 13,000 pigmented and non-pigmented cells. They proliferated as 731 
spheres and acquired the expression of CHX10 and nestin. Under differentiation conditions, the 732 
cells in spheres differentiated into MAP2-expressing neuronal cells and GFAP-expressing glial 733 
cells. Some undifferentiated nestin-positive cells remained in the center of spheres. When the 734 
cells from spheres were cultured in 2D under the same differentiation condition, they became 735 
flattened pigmented cells without neural markers.  736 
Collectively, the use of adult stem cells in organoid generation has been mostly from 737 
endoderm-derived epithelial tissues (intestine, colon, stomach, liver, pancreas, lung, and 738 
prostate), a few ectoderm-derived epithelial tissues (mammary gland, retina, and salivary gland), 739 
and mesoderm-derived epithelial tissue (fallopian tubes) (summarized in Table 2). There is no 740 
current attempt to bridge our understanding on the culturing conditions for adult stem cell-741 
derived and ESC- and iPSC-derived organoid cultures. Owing to the functions of stem cell 742 
niches in controlling proliferation and differentiation of adult stem cells, conditions mimicking 743 
the paracrine signals and the ECM components provided by their corresponding stem cell niches 744 
would be ideal for adult stem cell-derived organoids. However, only the design of intestinal 745 
organoid cultures was based on its niche. Other types of organoid cultures were developed by 746 
modifying the existing intestinal organoid conditions. Essential niche factors for other organ and 747 
tissue systems are not well characterized. 748 
4.3 EXPLORING DEVELOPMENTAL CUES IDENTIFIED DURING NORMAL 749 
FETAL TO ADULT TRANSITION. Recent studies on a number of human fetal tissues suggest 750 
the existence of fetal stem cells, which display distinct features and differentiation potentials 751 
from adult stem cells. For instance, stem cell populations have been identified and isolated from 752 
a number of human fetal tissues like neuroretina (Zhou et al., 2015), kidney (Da Sacco et al., 753 
2017), heart muscle (Leung et al., 2015), skeletal muscle (Alexander et al., 2016), pancreas 754 
(Bonfanti et al., 2015), intestine (Fernandez Vallone et al., 2016), and brain (Kallur et al., 2006; 755 
Kim et al., 2006), which are proliferative, self-renewing, and maintain tissue specific gene 756 
signatures when cultured in vitro. For instance, fetal enterospheres can be established from 757 
proliferative progenitors derived from human fetal intestinal tissues at gestational week 10 and 758 
the correspondingly-aged mouse fetal intestinal tissues at embryonic day 16.5 (Fordham et al., 759 
2013). These fetal enterospheres could be passaged for an extended period of time (up to 2 760 
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months for human and 2 years for mouse), were cultured in specific medium conditions distinct 761 
from adult organoids (ENR condition with the addition of PGE2 for human and ENR medium 762 
alone for mouse), and exhibited a smooth spheroid morphology in contrast to those organoids 763 
derived from Lgr5+ adult stem cells, which had budding protrusions on their surfaces. Apart 764 
from morphology, there are also distinct gene signatures that define adult stem cells and fetal 765 
progenitors. For instance, LGR5 specifically labeled adult stem cells in the intestine and the 766 
stomach (Barker et al., 2010; Huch et al., 2013b; Sato et al., 2009) but was expressed at 767 
relatively low levels in fetal tissues (Fernandez Vallone et al., 2016). Instead, fetal tissues were 768 
characterized by high expression of genes such as TROP2 and TNFRSF19 (Fernandez Vallone et 769 
al., 2016). So far, the differences found in organoid morphologies, culturing requirements, and 770 
gene expression profiles have been mainly characterized in adult and fetal intestines. Further 771 
investigation needs to be performed on other developing and adult organ systems to validate the 772 
generality of this phenomenon. These results so far support the notion that immature proliferative 773 
progenitors exist in mammalian fetal tissues and are developmentally distinct from adult stem 774 
cells in terms of the organoid structures they derive, their gene expression profiles, and their 775 
signaling requirements.  776 
Studying the natural fetal to adult transition of embryonic tissues bears enormous 777 
implications on how to promote terminal differentiation of ESC- and iPSC-derived tissue-778 
specific cell types, which very often suffer from an insufficient degree of cellular maturation. It 779 
is therefore imperative to promote studies in mammalian species to understand the signaling 780 
events and gene expression dynamics during the normal developmental transition of fetal tissues 781 
towards adulthood. Studies focusing on analyzing the stage-wise morphological and 782 
transcriptomic changes of fetal and perinatal tissues are particularly useful in identifying tissue-783 
specific and functionally-relevant gene markers to label and isolate stem cell and progenitor 784 
populations from differentiating human ESCs and iPSCs. By performing a three-way comparison 785 
between the transcriptomes of human intestinal organoids derived from pluripotent stem cells 786 
and human fetal and adult intestinal tissues, Finkbeiner et al. identified OLFM4 as a marker for 787 
intestinal tissue maturation, with enhanced specificity compared to the traditional adult stem cell 788 
marker LGR5 (Finkbeiner et al., 2015). In another study, microarray datasets of developing 789 
mouse heart tissues were collected and their transcriptomes were analyzed to reconstruct a gene 790 
regulatory network involved in heart maturation (Uosaki et al., 2015). Pathway analyses were 791 
employed to identify key pathways and upstream regulators activated at subsequent embryonic 792 
and adult stages. For example, the authors identified that the peroxisome proliferator-activated 793 
receptor (PPAR) pathway became increasingly active during subsequent developmental stages in 794 
the heart and therefore correlated to cardiac tissue maturation. In a similar study, matched human 795 
fetal atrial and ventricular heart tissues at first and second trimester stages corresponding to 7, 15, 796 
and 20 weeks of gestation were analyzed using microarrays (van den Berg et al., 2015). 797 
Ventricular- and atrial-specific gene signatures were identified. Interestingly, genes encoding 798 
histone H1 variants such as HIST1H3I, HIST1H2BM, and HIST1H2A1, and those for the ECM 799 
collagens such as COL1A2, COL2A1, and COL15A1 were downregulated and upregulated 800 
respectively in second trimester heart tissues as compared to those from the first trimester, 801 
suggestive of a developmental change in gene expression pattern during human heart tissue 802 
maturation. In order to translate these transcriptomic studies into useful information for in vitro 803 
organoid cultures, gain- and loss-of-function experiments can be carried out in animals to 804 
identify key molecules and pathways regulating the maturation of specific tissues.  805 
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4.4 CURRENT ATTEMPTS ON PROMOTING ORGANOID MATURATION. A 806 
number of studies have attempted to promote in vitro maturation in human organoids. One 807 
approach aims to generate reporter lines that allow isolation of the rare adult stem cell 808 
populations from differentiated human ESC and iPSC cultures. Using zinc finger genome editing 809 
technology, Forster et al. engineered a GFP reporter insertion into the endogenous locus of the 810 
intestinal adult stem cell marker LGR5 (Forster et al., 2014). By flow cytometry-assisted sorting 811 
of teratoma tissues derived from this knock-in human iPSC line, the authors were able to isolate 812 
LGR5+ progenitors that could form organoids similar in culturing conditions and differentiation 813 
potentials to intestinal organoids derived from LGR5+ adult stem cells. They additionally found 814 
that maintenance of these adult stem cell-like derived organoids required both WNT and Notch 815 
signaling. A second approach aims to identify conditions for maturation either empirically or by 816 
inference from culturing conditions of adult stem cells. For instance, it was found that maturation 817 
medium containing T3 hormone significantly promoted the maturation of in vitro human ESC- 818 
and iPSC-derived cardiomyocytes, which corresponded to second trimester human heart tissues 819 
(van den Berg et al., 2015). The maturation status of those cardiomyocytes not treated with the 820 
maturation medium remained at first trimester. One key feature of primate cerebral cortex is the 821 
presence of gyrification. Human cerebral organoids generated so far lack cortical folding. A 822 
recent study suggests that enhanced AKT signaling caused by PTEN mutation promotes 823 
formation of folds in human cerebral organoids (Li et al., 2017). It is unknown whether in vitro 824 
activation of AKT pathway may promote maturation of cerebral cortical organoids. Many adult 825 
stem cell organoid markers are WNT targets, suggesting that adult organoids likely have high 826 
WNT signaling and activation of WNT signaling could promote fetal-to-adult transition of fetal 827 
organoids. Indeed, it has been shown that inclusion of Wnt3A ligand in cultures for fetal 828 
progenitor derived enterospheres could promote their maturation into adult stem cell-like derived 829 
organoids (Fordham et al., 2013). Some other studies have started to exploit whether ECM and 830 
bioengineered scaffolds may provide cues for maturation. For instance, salivary gland spheres 831 
were expanded in Matrigel and then differentiated into organoids in a mixture of Matrigel and 832 
collagen (Nanduri et al., 2014). Another recent study reports improved maturation and 833 
engraftment of lung organoids by using a microporous poly(lactide-co-glycolide) scaffold (Dye 834 
et al., 2016). These experiments strongly suggest that, to a certain extent, maturation of 835 
organoids is achievable in vitro.  836 
 837 
5 BIOMEDICAL APPLICATIONS AND PERSPECTIVES OF NEXT GENERATION 838 
HUMAN ORGANOIDS 839 
A number of excellent reviews have recently been published on the usage of organoids in 840 
pharmaceutical and clinical research. Here, we aim to highlight the potential improvements on 841 
organoid synthesis that our review discusses and propose studies that will benefit a range of 842 
biomedical applications including disease modeling, drug discovery, and tissue transplantation.  843 
5.1 MIMICKING THE COMPLEX CELLULAR HETEROGENEITY OF 844 
UNDERSTUDIED ORGANS AND TISSUES. So far, most of our discussion has been limited 845 
to internal organs and brain tissues. Organoids or 3D cultures for many other tissues, especially 846 
those that involved the incorporation of ectoderm-derived cell types, such as inner ears, cranial 847 
ganglia, skin, limbs, and eyes, have been less commonly attempted. The major difficulty 848 
associated with synthesizing organoids for these tissues is the lack of robust differentiation 849 
approaches for the co-induction of specific progenitors in the right proportions from the same or 850 
different germ layers. For instance, the mammalian ear, which includes the outer, middle, and 851 
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inner ear, is derived from cell types generated from all three germ layers. Defects in any of the 852 
cell components could lead to conductive or sensory hearing loss. Another example is the 853 
ganglionic structures that develop in the head region, such as the trigeminal and 854 
vestibulocochlear ganglia, the latter of which contributes to the inner ear. Disorders like sensory 855 
or age-related hearing loss and migraine arise from malfunctions of these ganglia. These ganglia 856 
are composed of sensory neurons, which are derived from cranial placodes, and glial cell types, 857 
from neural crest. Both cranial placodes and neural crest are ectoderm derived but their induction 858 
regimes in ESCs and iPSCs differ dramatically (Dincer et al., 2013; Leung et al., 2013; Leung et 859 
al., 2016; Menendez et al., 2011; Mica et al., 2013). Neurovascular networks for internal organs 860 
are composed of autonomic neurons, endothelial cells, and vascular smooth muscle cells. The 861 
introduction of an intact neurovascular network into organoids for internal organs will allow 862 
more precise disease modeling, for instance, for Hirschsprung disease (Workman et al., 2017) or 863 
other genetic disorders with a disrupted neurovascular development. A recent study found that 864 
proper differentiation of hESC-derived autonomic neurons was dependent on contacts with 865 
endothelial cells and vascular smooth muscle cells and that the co-cultures of all three cell types 866 
led to the development of an organized neurovascular network (Acevedo et al., 2015). This again 867 
demonstrates that physiologically relevant progenitors can self-organize to reform endogenous 868 
tissue-like structures in vitro.  869 
5.2 ENHANCING SAFETY, EFFICACY, AND COST-EFFECTIVENESS OF DRUG 870 
TESTING. Drug development is an expensive (1.78 billion US dollars for a new molecular 871 
entity) and lengthy (average 13.5 years) process (Paul et al., 2010). The biggest challenge facing 872 
the pharmaceutical industry is the high attrition rate in drug development. The product failing 873 
rates in the United States, Europe, and Japan between 1990 and 2004 had drastically increased, 874 
approximately 75% at preclinical phase, 70% at phase I, 55% at both phase II and phase III 875 
(Ledford, 2011). A recent study analyzing drug attrition from four major pharmaceutical 876 
companies shows that drug toxicity was the primary cause of attrition at preclinical phase and 877 
clinical phase I (Waring et al., 2015). The likelihood of final approval counting from the start of 878 
clinical phase I was only about 10% (Hay et al., 2014; Kola and Landis, 2004). The main causes 879 
of attrition were lack of efficacy and safety, each contributing to approximately 30% of failures 880 
(Kola and Landis, 2004). During 2007-2010, 66% of phase III submission failures were 881 
attributable to lack of efficacy, particularly in the therapeutic areas of oncology and 882 
neurodegeneration, and 21% of failures were caused by safety issues (Arrowsmith, 2011). 883 
Moreover, drug withdrawal from the market due to toxicology has a remarkable impact on the 884 
pharmaceutical industry and also on patients. Adverse drug reactions are serious problems and 885 
considerably increase morbidity, mortality, and health care costs (Pirmohamed et al., 2004). 886 
Drug-induced liver injury was the most common reason for the withdrawal of clinical drugs from 887 
the worldwide market during 1953-2013 (18% of all withdrawals) (Onakpoya et al., 2016). 888 
Another study reported the top three reasons for the post-marketing withdrawal in the EU during 889 
2002-2011 were cardiovascular toxicity, hepatotoxicity, and neurotoxicity (McNaughton et al., 890 
2014). To improve R&D productivity and quality of health care, obtaining human proof-of-891 
concept data early in drug development and identifying risks at the preclinical phase are crucial. 892 
An ideal in vitro model for preclinical drug testing should mimic human pathophysiology 893 
to promote accurate prediction of drug efficacy and toxicity. Next generation human cell-derived 894 
organoids generated by the incorporation of the correct cellular heterogeneity, maturation factors, 895 
and designer matrices would bear a closer resemblance to the in vivo tissues and organs than 896 
conventional 2D cultures and 3D organoids. They would have close to native cellular 897 
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composition and could better predict drug efficacy and toxicity at a tissue or organ level. Also 898 
many drug-induced injuries are not caused by direct effects on parenchymal cells but rather 899 
caused by immune responses or non-specific systemic effects from non-parenchymal cell types. 900 
For instance, some compounds show liver toxicity in vivo but are not toxic to hepatocytes or only 901 
at extremely high concentrations, indicating that in vitro testing using only hepatocytes is not 902 
adequate to predict hepatotoxicity (Godoy et al., 2013). Non-parenchymal cells in the liver, such 903 
as Kupffer cells and hepatic stellate cells, may contribute to inflammation during drug-induced 904 
liver injury (Godoy et al., 2013). Liver organoids with Kupffer cells or hepatic stellate cells 905 
would predict such hepatotoxicity more accurately than those with primary human hepatocytes, 906 
which is the current gold standard for in vitro drug testing. Hepatic stellate cells also contribute 907 
to the development of liver fibrosis. Recently human hepatic organoids derived from HepaRG 908 
and primary human hepatic stellate cells have been used to evaluate drug-induced liver fibrosis 909 
(Leite et al., 2016). Liver organoids derived from human ESCs/iPSCs with normal genotypes 910 
would be superior to HepaRG, which is a human hepatocellular carcinoma-derived hepatic 911 
progenitor cell line. Organoids derived from human iPSCs of different genetic backgrounds 912 
would help develop personalized toxicology, which will pave the way to precision medicine. A 913 
study successfully reproduced individual differences in drug metabolism capacity and 914 
responsiveness by using a panel of human iPSC-derived hepatocyte-like cells (Takayama et al., 915 
2014). Liver organoids with bile duct-like structures formed by including cholangiocytes would 916 
predict drug-induced cholestasis. 3D hepatocyte spheroids derived from human ESCs and iPSCs 917 
exhibited increased expression of drug metabolizing enzymes and transporters and increased 918 
sensitivity to tested drug compounds, compared to traditional hepatocellular carcinoma-derived 919 
cell lines like HepG2 cells (Takayama et al., 2013). Similarly, neurotoxicity has contributed to 920 
attrition of drug candidates. A recent study by (Schwartz et al., 2015) has constructed neural 921 
organoids using multi-lineage progenitors to mimic the normal composition of cell types during 922 
brain development. The system has successfully predicted known toxins in blind screens. Due to 923 
the technical difficulty in establishing and maintaining organoid cultures, 2D cell models still 924 
dominate the early phases of drug development, such as the lead generation phase. However, due 925 
to their enhanced ability to mimic human physiology, organoid cultures are especially valuable 926 
in lead optimization and preclinical development. 927 
Increasing demands from patient advocacy groups and the anticipation of changing 928 
government policies to introduce new competition among pharmaceutical companies have 929 
continuously added tremendous pressure to reduce drug prices and a demand to enhance cost 930 
effectiveness in the drug development pipeline. Stem cell differentiation relies heavily on growth 931 
factors, which are expensive and short-lived. 2D differentiation allows easy access of growth 932 
factors to cultured cells and, in many cases, allowed close to homogeneous induction of 933 
progenitor cell types from human ESCs and iPSCs. Coupling an initial 2D differentiation 934 
protocol followed by organoid formation would enhance cost-effectiveness. On the other hand, 935 
small molecules have been developed to replace growth factors. They are smaller in molecular 936 
mass, cheaper and more stable than growth factors. A study testing small molecules for replacing 937 
growth factors used in hepatic differentiation of hESCs has shown that the cost could be reduced 938 
by 67% (Tasnim et al., 2015). Small molecules will have better ability to penetrate organoid 939 
structures compared to growth factors. Therefore, they are better suited to be employed at later 940 
stages of organoid cultures. 941 
5.3 FACILITATING THE SETUP OF VARIOUS BIOENGINEERING 942 
APPROACHES. In static cultures, cells in organoids do not experience mechanical signals as 943 
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they do in the body. Dynamic (perfusion) cultures can provide the necessary fluid shear stress 944 
and other forces. They also can facilitate the efficient delivery of nutrients and oxygen. Perfusion 945 
bioreactors, which allow cultures in much larger scales than microfluidic devices, have been 946 
used in tissue engineering for bones (Gaspar et al., 2012) and intestinal tissues (Kim et al., 2007). 947 
A recent study reports human liver organoids formed with diameters up to a few millimeters 948 
from the self-organization of a conglomerate of genetically engineered adult hepatocytes, liver 949 
sinusoidal endothelial cells, and mesenchymal stem cells in a perfusion bioreactor 950 
(Ramachandran et al., 2015), suggesting that the principle of self-organization might be 951 
applicable to adult cell populations. On the other hand, microfluidic devices have also been used 952 
for perfusion cultures. Organ-on-a-chip is a microfluidic cell culture device with hollow 953 
microchannels onto which cells are cultured and through which medium is flowed (Bhatia and 954 
Ingber, 2014). Organ-on-a-chip devices can be used to culture one or more types of cells 955 
simultaneously and to mimic pathophysiological conditions at different levels, such as at the 956 
tissue/organ level, where cells from the same tissues and organs are cultured on a chip, or at 957 
organism level, where cells from different tissues and organs are used (Huh et al., 2011). Organ-958 
on-a-chip and human-on-a-chip approaches enable high throughput assays. By using an organ-959 
on-a-chip device, the organoid-based in vitro model can predict drug response and toxicity at an 960 
organismal level. A pioneering human-on-a-chip study has combined multiple cell types in a 961 
multi-channel 3D microfluidic cell culture system (Zhang et al., 2009). This system included cell 962 
lines representing liver, kidney, lung, and adipose tissues grown in separate channels and 963 
cultured with a common medium mimicking blood flow. Similarly, different types of organoids 964 
could be cultured in such a multi-channel microfluidic device to build a human-on-a-chip. 965 
Organoids could be formed in other culture systems and then transferred to the microfluidic 966 
device or could be formed directly in the microfluidic device. Two recent reviews have described 967 
the potential of organoid-on-a-chip in biomedical research and applications (Konar et al., 2016; 968 
Skardal et al., 2016). Microfabrication can produce topological patterns that are particularly 969 
useful for the study of neuronal behavior. Jeong, et al. have created a deep hemicylindrical, 970 
microchannel-networked, concave array system for the formation of nerve-like networks (Jeong 971 
et al., 2015). Rat embryonic neural progenitor cells self-aggregated into host neurospheroids in 972 
concave microwells and satellite neurospheroids in deep hemicylindrical channels. Neurites grew 973 
along channels and were bridged by satellite neurospheroids to connect host neurospheroids 974 
together. The neural network was shown to transmit signals from one neurospheroid to another. 975 
Taken together, other components of our approach, such as the use of empirically tested design 976 
matrices to control the microenvironments and the administration of maturation factors specific 977 
for different organs and tissues, should also be considered in these systems.   978 
5.4 MEETING THE DEMANDS FOR HUMAN TISSUES FOR 979 
TRANSPLANTATION. Demand for raw tissue materials for transplantation calls for a supply of 980 
in vitro derived, xeno-free, and high-quality human tissues. For instance, for end-stage organ 981 
failure, such as liver and heart failure, organ transplantation is the only available treatment. 982 
Renal replacement therapy can treat end-stage renal diseases, but kidney transplantation 983 
represents the best treatment both for patients’ quality of life and cost-effectiveness. Over 4,500 984 
people in Canada (2015 data, https://www.cihi.ca/en/types-of-care/specialized-services/organ-985 
replacements/e-statistics-on-organ-transplants-waiting), 120,000 people in the U.S. (2015 data, 986 
www.organdonor.gov), 86,000 in the European Unions plus Iceland, Norway, and Turkey 987 
(December 2013 data, 988 
http://ec.europa.eu/health//sites/health/files/blood_tissues_organs/docs/ev_20141126_factsfigure989 
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s_en.pdf), and 1.5 million in China (2007 data, 990 
http://www.ghgj.org/Living%20Organ%20Transpl.pdf) are on the waiting list for organ 991 
transplant. Most of these people need kidney transplantation (>80%), followed by liver (~10%), 992 
heart (<5%), lung (~1%), and pancreas (~1%). In the U.S., from early 1990s onwards, the gap 993 
between the number of people waiting for a transplant and the number of organ donors has 994 
continued to widen to over 7 times. Added to the demand, organ donation is still less common in 995 
many countries such as China and Japan. Apart from internal organs, there is also increasing 996 
demand for human cell and tissue materials to regrow missing bones, muscles, connective tissues, 997 
neural plexi, and skin in the face, neck, and extremities resulting from injuries in wars, motor 998 
vehicle-related accidents, burns, and natural disasters (Jalali et al., 2014; van Zuijlen et al., 2015). 999 
There are ongoing clinical trials sponsored by the U.S. NIH to conduct transplantation 1000 
trials using human ESC- and iPSC-derived cardiac progenitors and retinal pigmented epithelial 1001 
cells (www.clinicaltrials.gov). Clinical data for other more highly demanded tissues for 1002 
transplantation such as kidney, liver, and pancreas are urgently needed. In animal studies, 1003 
xenographic transplantation into adult mouse tissues of human liver organoids generated from a 1004 
composite aggregate of liver progenitors, endothelial cells, and mesenchyme stem cells has been 1005 
conducted with success (Takebe et al., 2014). To extend its application, such a multi-lineage 1006 
recombination method using organ-specific progenitors and vascular and mesenchymal stem cell 1007 
types has been used to successfully reconstruct composite organoids for intestine, lung, kidney, 1008 
heart, and brain (Takebe et al., 2015). Liver and other organoids derived from these and other 1009 
studies suffer from a limitation in size, which usually ranged in the millimeter scale, thereby 1010 
restricting their direct usage in transplantation. To resolve this issue, de-cellularized liver 1011 
scaffolds from animals and human cadavers or cell-free scaffolds generated from 3D printing 1012 
technology could be made and seeded with dissociated organ-specific precursors or directly with 1013 
organoids containing parenchymal, vascular, and other supporting cell types (Collin de l'Hortet 1014 
et al., 2016). Together with physiologically relevant culturing methods and bioreactor cultures, 1015 
these scaffolds could physically support the growth of larger organ structures in vitro. Of interest, 1016 
whole organ de-cellularization has been achieved for liver and a number of other organs 1017 
including heart, lung, kidney, and pancreas (Scarritt et al., 2015). One of the main challenges in 1018 
this type of study is to maintain the architecture and composition of the ECM during the de-1019 
cellularization process, such as collagen, laminin, elastin, and fibronectin, and biologically-active 1020 
molecules, such as growth factors. Synthesizing cell-free scaffolds with xeno-free designer 1021 
matrices and 3D printing technology is an alternative to using de-cellularized organ scaffolds. A 1022 
few studies have attempted to re-cellularize lung and kidney scaffolds derived from rhesus 1023 
monkey’s organs with undifferentiated human ESCs (Scarritt et al., 2015). The resultant 1024 
chimeric organs contain ESCs expressing non-specific markers. Differentiated ESC- and iPSC-1025 
derived organ progenitors can instead be used for re-cellularization to promote tissue-specific 1026 
differentiation. For advanced clinical studies, patient-specific iPSCs derived with xeno-free 1027 
methods should be used to respond to ethical concerns regarding preservation of human embryos 1028 
and to reduce chances of immune rejection upon transplantation. 1029 
 1030 
6 CONCLUSION 1031 
In this review, we have highlighted new perspectives and directions that have been 1032 
initiated in recent organoid studies. The new development will act as a catalyst for the organoid 1033 
field and provide new directions to other fields, particularly for developmental biology, 1034 
embryonic stem cell studies, and adult stem cell biology. 1035 
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By applying the principle of reverse engineering, we propose a new pipeline for human 1036 
organoid generation that potentially can greatly enhance the efficiency of generation, the 1037 
physiological relevance, and the functionality of in vitro derived human organoids. By exploiting 1038 
the self-organizing property of embryonic progenitors, the dissociation-aggregation approach 1039 
allows the generation of organoids with enhanced native cellular composition as well as more 1040 
flexible experimental designs and multi-stage quality controls as progenitor raw materials can be 1041 
generated in batches, cryopreserved, thawed, and expanded before organoid formation. Designer 1042 
matrix, whether it is tailor-made, native or a composite of both, helps construct the native micro- 1043 
and matrix environment organoid cell types encountered during aggregation, self-organization, 1044 
and differentiation. Lastly, a rigorous maturation schematic for different organoid systems 1045 
permits the generation of fully-functional and terminally-differentiated cell types from human 1046 
organoids that can be used in a wider range of applications and more closely mimic normal 1047 
human physiology.  1048 
To significantly advance human organoid synthesis technology for various applications, 1049 
there is an urgency to synthesize knowledge and technologies developed in different fields 1050 
including stem cell biology, developmental biology, matrix biology, systems biology, 1051 
bioengineering, material science, biostatistics, and bioinformatics. Such endeavors have been 1052 
made in various fronts and have to be continuously encouraged by government institutions, 1053 
sponsoring institutions, and other private funding agencies. Continuous education of the public 1054 
and communications among scientists, the public media, and the public are also paramount in 1055 
reducing unwarranted skepticism for using stem cell-derived cell types and tissues for basic 1056 
research and biomedical applications. Various scientific fields, when proposing research, on the 1057 
other hand, should also avoid over-optimism and fairly evaluate the beneficial effects of stem 1058 
cell products.  1059 
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Figure Captions 1702 
Figure 1. A novel pipeline for developing future protocols to generate organoids.   1703 
 1704 
Figure 2. Increased control on the timing of progenitor incorporation into organoid structures.  1705 
 1706 
Figure 3. Dissection of the self-organization process.  1707 
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Table 1 – Summary of pioneered animal studies for organ progenitor aggregation  1708 
  1709 






Ectoderm Inner ear Gallus gallus   (Orr, 1968) 
 Inner ear Mus musculus E13-E14 6 (Bianchi et al., 2002) 
 Cerebral cortex, 
brainstem spinal 
cord 
Mus musculus   (Crain and Bornstein, 1972) 
 Retina Gallus gallus   (Layer et al., 2001) 
 Submandibular 
gland 
Mus musculus E13-E17 4 (Wei et al., 2007)  
Mesoderm Kidney Mus musculus E11.5 21 (Benedetti et al., 2016; Xinaris et al., 2012) 
 Heart Gallus gallus 2.5, 4 or 7d  (McDonald and Sachs, 1975) 
  Gallus gallus, Rat 50h, 12d  (Nag et al., 1980) 
Endoderm Pancreas Mus musculus E10.5 14 (Greggio et al., 2013; Greggio et al., 2014) 
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Table 2. Adult stem cell-derived organoids 1710 
Germ 
layer 
Tissue Species Niche factors for 
expansion 




Endoderm Intestine Mouse EGF, Noggin, R-spondin 1, 
Y-27632 (for single cell 
culture) 
Matrigel Same as 
expansion 
condition 
(Sato et al., 2009) 








(Sato et al., 2011) 
Endoderm  Colon Mouse EGF, Noggin, R-spondin 1, 
Wnt3A, Y-27632 (for single 
cell culture in the first 2 
days) 
Matrigel Withdrawal of 
Wnt3A  
(Sato et al., 2011) 








(Sato et al., 2011) 
Endoderm  Stomach Mouse EGF, Noggin, R-spondin 1, 
Wnt3A, gastrin, FGF10, Y-
27632 (for single cell 
culture in the first 2 days),  
Matrigel Wnt3A reduction (Barker et al., 
2010) 
Endoderm Stomach Human EGF, Noggin conditioned 
medium, R-spondin 1 
conditioned medium, Wnt 
conditioned medium, 
gastrin, FGF10, A-83-01, 
nicotinamide (for single cell 
culture), Y-27632 (for single 
cell culture) 
Matrigel Nicotinamide for 
gland-type 
organoids; 
Withdrawal of Wnt 
for pit-type 
organoids 
(Bartfeld et al., 
2015) 
Endoderm Liver Mouse Gastrin, EGF, R-spondin 1, 
FGF10, nicotinamide, HGF, 
Y-27632 (for single cell 
culture in the first 4 days), 
Noggin and Wnt3a (for the 
first 4 days) 
Matrigel Withdrawal of R-
spondin 1, HGF 
and nicotinamide 
and addition of 
EGF, FGF10, A-
83-01, DATP and 
dexamethasone 
(Huch et al., 
2013b) 
Endoderm  Liver Human Gastrin, EGF, R-spondin 1 
conditioned medium, 
FGF10, nicotinamide, HGF, 
A-83-01, Forskolin (a cAMP 
pathway agonist); For the 
first 3 days also including 
Y-27632, Noggin and Wnt 
conditioned medium   
Matrigel First BMP7 for 2-4 
days and then the 
withdrawal of N-
acetylcysteine, R-
spondin 1, FGF10, 
nicotinamide and 
Forskolin and 
addition of FGF19, 
DAPT and 
dexamethasone 
(Huch et al., 
2015) 
Endoderm  Pancreas Mouse Gastrin, EGF, R-spondin 1, 
Noggin, FGF10, 
nicotinamide, Y-27632 (for 
single cell culture in the first 
4 days) 
Matrigel In suspension 
0.2% FBS, Activin 
A for 3 days, then 
with indolactam-V, 
FGF10, 2% FBS 
for 4-5 days, and 
then with B27, 
Noggin, retinoic 




cyclopamine for 6 
days, finally with 
B27 and DBZ for 
2-4 days before in 
vivo 
transplantation in 
kidney capsule   
Endoderm  Pancreas Mouse Gastrin, EGF, R-spondin 1, 
Noggin, FGF10, 
nicotinamide, Y-27632 (for 
single cell culture in the first 
4 days) 
Matrigel  (Boj et al., 2015) 
Endoderm  Pancreas Human EGF, R-spondin 1 
conditioned medium, Wnt3a 
conditioned medium, 
Noggin conditioned 
medium, gastrin, FGF10, 
nicotinamide, A-83-01, 
prostaglandin E2 
Matrigel  (Boj et al., 2015) 
Endoderm  Lung Human 10% FCS, hydrocortisone, 
insulin, transferrin, 
triiodothyronine, 









(Kumar et al., 
2011) 
Endoderm  Lung Mouse Insulin, transferrin, cholera 
toxin, EGF, bovine pituitary 








lung stromal cells 
(Barkauskas et 
al., 2013) 
Endoderm  Prostate Mouse/h
uman 
EGF, Y-27632, 5% 
Matrigel, 5% charcoal-
stripped FBS, DHT 
Flotation  Same as 
expansion 
condition 
(Chua et al., 
2014) 
Endoderm Prostate Mouse EGF, Noggin, R-spondin, 
A-83-01, DHT 
Matrigel Same as 
expansion 
condition 
(Karthaus et al., 
2014) 
Endoderm Prostate Human EGF, Noggin, R-spondin, 
A-83-01,  DHT, FGF10, 
FGF2, prostaglandin E2, 
nicotinamide, SB202190 
Matrigel Same as 
expansion 
condition 




Mouse Insulin, hydrocortisone, 
prolactin, 1% FCS 
Matrigel Same as 
expansion 
condition 




Mouse Hydrocortisone, insulin, 
EGF, FGF2, FGF10, 










(Jamieson et al., 
2016) 




glass in EGF 
containing serum-
free medium 




Mouse EGF, FGF2, insulin, 
dexamethasone, Y-27632 
Matrigel Intact spheres in 
collagen-Matrigel 
mixture (4:6) and 







Human Wnt3A conditioned 
medium, R-spondin 1 




Matrigel Same as 
expansion 
condition 
(Kessler et al., 
2015) 
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